Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300636 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP2C19LMNANPSR1JAK2 | |
| SCHEMBL18106489 | 0.88 | ALDH1A1 (0.46) | ALDH1A1CYP2C19LMNANPSR1JAK2 | |
| SCHEMBL29896531 | 0.81 | ALDH1A1 (0.52) | ALDH1A1CYP2C19LMNANPSR1JAK2 | |
| SCHEMBL4298901 | 0.81 | CPA1 (0.46) | ALDH1A1CYP2C19LMNACPA1SMN1; SMN2 | |
| SCHEMBL4298905 | 0.81 | CPA1 (0.46) | ALDH1A1CYP2C19LMNACPA1SMN1; SMN2 | |
| SCHEMBL6226912 | 0.81 | ALDH1A1 (0.49) | ALDH1A1CYP2C19LMNACPA1 | |
| SCHEMBL18106777 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP2C19LMNACNR1L3MBTL1 | |
| SCHEMBL2545170 | 0.80 | ALDH1A1 (0.51) | ALDH1A1CYP2C19LMNAMAPTSMN1; SMN2 | |
| SCHEMBL18106499 | 0.79 | ALDH1A1 (0.50) | ALDH1A1CYP2C19LMNANPSR1HSP90AA1 | |
| SCHEMBL18578806 | 0.79 | ALDH1A1 (0.40) | ALDH1A1CYP2C19LMNAHSP90AA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640361-B9 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-1640361-B1 | ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST | SUMITOMO CHEMICAL CO (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7632970-B2 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1640361-A2 | ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060161006-A1 | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst | RAD18, UTP18, UBE2G2 | ALDH1A1 2730/4885CYP2C19 121/4885LMNA 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.